• by Nina Lentini  @Nina_Lentini, March 30, 2016

Pfizer has come out on top in a new global ranking released Tuesday by Interbrand Health that identifies the biopharma brands that are addressing and meeting today’s healthcare needs.

Looking to the future, healthcare professionals desire a commitment to innovative healthcare solutions that go “beyond the pill,” says the company in a news release. As a result, leading biopharma companies are adapting their business models, increasing transparency, exploring nontraditional solutions in areas like digital therapies, and ramping up their corporate citizenship activities.

“Biopharma is at a pivotal moment, and the time for change is now,” said Jane Parker, InterbrandHealth’s CEO.

Best Pharma Brands ranks these leading companies by qualifying the industry’s definition of value through brand, then quantifying the corporate brand’s contribution to business performance. The ranking identifies the 10 most valuable biopharma brands. In total, these 10 brands represent approximately USD $129 billion in brand value. Here is the full list:

• #1 Pfizer (USD $19.985 billion)

• #2 Roche Group (USD $15.479 billion)

• #3 Merck & Co., Inc., Kenilworth, N.J., U.S.A. (USD $13.880 billion) [Note: MSD outside of the United States & Canada] 

• #4 Janssen: The Janssen Pharmaceutical Companies of Johnson & Johnson (USD $13.866 billion)

• #5 Novartis (USD $13.496 billion)

• #6 Amgen (USD $13.461 billion)

• #7 Gilead Sciences (USD $13.361 billion)

• #8 Novo Nordisk (USD $10.206 billion)

• #9 AstraZeneca (USD $8.123 billion) 

• #10 GSK (USD $6.778 billion)

Parker commented that “these 10 biopharma brands are embracing a strategy that is somewhat new to the health and life sciences sector: they are effectively leveraging their corporate brands and, in doing so, they are growing their businesses, fueling innovation, and developing meaningful solutions for patients on a global scale.” 

Best Pharma Brands is powered by global research data, feedback from HCPs, and data-driven insights. The underlying methodology mirrors Interbrand’s Best Global Brands, which demonstrates that strong brands can withstand market volatility and are more likely to outperform key financial indices like the S&P 500.